A simplified purification protocol for recombinant adeno-associated virus vectors

Molecular Therapy Methods and Clinical Development

Volumn 1, Issue , 2014, Pages 14034-

  Potter, Mark ^a   Lins, Bridget ^a   Mietzsch, Mario ^b   Heilbronn, Regine ^b   Van Vliet, Kim ^a   Chipman, Paul ^a   Agbandje McKenna, Mavis ^a   Cleaver, Brian D ^a   Clément, Nathalie ^a,c   Byrne, Barry J ^a,c   Zolotukhin, Sergei ^a,c  

^a UNIVERSITY OF FLORIDA   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENO ASSOCIATED VIRUS VECTOR; CAPSID PROTEIN; CITRATE SODIUM; IODIXANOL;

AMINO TERMINAL SEQUENCE; ARTICLE; ASSAY; BIOCHEMISTRY; CELL LYSATE; CENTRIFUGATION; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; ELECTRON MICROSCOPY; FLOCCULATION; GOOD MANUFACTURING PRACTICE; GREEN CELL FLUORESCENT ASSAY; HUMAN; HUMAN CELL; ION EXCHANGE CHROMATOGRAPHY; ISOELECTRIC POINT; NONHUMAN; PH; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SCALE UP; SEROTYPE; SUPERNATANT; VIRUS CAPSID; VIRUS PARTICLE; VIRUS PURIFICATION;

EID: 85015705723     PISSN: None     EISSN: 23290501     Source Type: Journal    
DOI: 10.1038/mtm.2014.34     Document Type: Article

References (30)

1. 1 Mueller, C, Flotte, TR, Clinical gene therapy using recombinant adeno-associated virus vectors. Gene Ther 15 (2008), 858–863.
2. 2 High, KA, Aubourg, P, rAAV human trial experience. Methods Mol Biol 807 (2011), 429–457.
3. 3 High, KA, Gene therapy for haemophilia: a long and winding road. J Thromb Haemost 9:suppl. 1 (2011), 2–11.
4. 4 Mingozzi, F, High, KA, Immune responses to AAV in clinical trials. Curr Gene Ther 11 (2011), 321–330.
5. 5 Asokan, A, Schaffer, DV, Samulski, RJ, The AAV vector toolkit: poised at the clinical crossroads. Mol Ther 20 (2012), 699–708.
6. 6 Nathwani, AC, Tuddenham, EG, Rangarajan, S, Rosales, C, McIntosh, J, Linch, DC, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 365 (2011), 2357–2365.
7. 7 Zhong, L, Li, B, Mah, CS, Govindasamy, L, Agbandje-McKenna, M, Cooper, M, et al. Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc Natl Acad Sci USA 105 (2008), 7827–7832.
8. 8 Zolotukhin, S, Byrne, BJ, Mason, E, Zolotukhin, I, Potter, M, Chesnut, K, et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther 6 (1999), 973–985.
9. 9 Clark, KR, Liu, X, McGrath, JP, Johnson, PR, Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses. Hum Gene Ther 10 (1999), 1031–1039.
10. 10 Auricchio, A, O“Connor, E, Hildinger, M, Wilson, JM, A single-step affinity column for purification of serotype-5 based adeno-associated viral vectors. Mol Ther 4 (2001), 372–374.
11. 11 Brument, N, Morenweiser, R, Blouin, V, Toublanc, E, Raimbaud, I, Chérel, Y, et al. A versatile and scalable two-step ion-exchange chromatography process for the purification of recombinant adeno-associated virus serotypes-2 and -5. Mol Ther 6 (2002), 678–686.
12. 12 Okada, T, Nonaka-Sarukawa, M, Uchibori, R, Kinoshita, K, Hayashita-Kinoh, H, Nitahara-Kasahara, Y, et al. Scalable purification of adeno-associated virus serotype 1 (AAV1) and AAV8 vectors, using dual ion-exchange adsorptive membranes. Hum Gene Ther 20 (2009), 1013–1021.
13. 13 Kaludov, N, Handelman, B, Chiorini, JA, Scalable purification of adeno-associated virus type 2, 4, or 5 using ion-exchange chromatography. Hum Gene Ther 13 (2002), 1235–1243.
14. 14 Zolotukhin, S, Potter, M, Zolotukhin, I, Sakai, Y, Loiler, S, Fraites, TJ Jr, et al. Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 28 (2002), 158–167.
15. 15 Davidoff, AM, Ng, CY, Sleep, S, Gray, J, Azam, S, Zhao, Y, et al. Purification of recombinant adeno-associated virus type 8 vectors by ion exchange chromatography generates clinical grade vector stock. J Virol Methods 121 (2004), 209–215.
16. 16 Hellström, M, Ruitenberg, MJ, Pollett, MA, Ehlert, EM, Twisk, J, Verhaagen, J, et al. Cellular tropism and transduction properties of seven adeno-associated viral vector serotypes in adult retina after intravitreal injection. Gene Ther 16 (2009), 521–532.
17. 17 Zhou, J, Yang, X, Wright, JF, High, KA, Couto, L, Qu, G, PEG-modulated column chromatography for purification of recombinant adeno-associated virus serotype 9. J Virol Methods 173 (2011), 99–107.
18. 18 Venkatakrishnan, B, Yarbrough, J, Domsic, J, Bennett, A, Bothner, B, Kozyreva, OG, et al. Structure and dynamics of adeno-associated virus serotype 1 VP1-unique N-terminal domain and its role in capsid trafficking. J Virol 87 (2013), 4974–4984.
19. 19 Salganik, M, Venkatakrishnan, B, Bennett, A, Lins, B, Yarbrough, J, Muzyczka, N, et al. Evidence for pH-dependent protease activity in the adeno-associated virus capsid. J Virol 86 (2012), 11877–11885.
20. 20 Kohlbrenner, E, Aslanidi, G, Nash, K, Shklyaev, S, Campbell-Thompson, M, Byrne, BJ, et al. Successful production of pseudotyped rAAV vectors using a modified baculovirus expression system. Mol Ther 12 (2005), 1217–1225.
21. 21 Mietzsch, M, Grasse, S, Zurawski, C, Weger, S, Bennett, A, Agbandje-McKenna, M, et al. OneBac: platform for scalable and high-titer production of adeno-associated virus serotype 1-12 vectors for gene therapy. Hum Gene Ther 25 (2014), 212–222.
22. 22 Grimm, D, Streetz, KL, Jopling, CL, Storm, TA, Pandey, K, Davis, CR, et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441 (2006), 537–541.
23. 23 Gellan, E, Martin, GF, Cumming, RH, Flocculation of cell debris from ultrasonicated Escherichia coli. Biotechnol Bioeng 37 (1991), 697–702.
24. 24 Nam, HJ, Gurda, BL, McKenna, R, Potter, M, Byrne, B, Salganik, M, et al. Structural studies of adeno-associated virus serotype 8 capsid transitions associated with endosomal trafficking. J Virol 85 (2011), 11791–11799.
25. 25 Smith, RH, Levy, JR, Kotin, RM, A simplified baculovirus-AAV expression vector system coupled with one-step affinity purification yields high-titer rAAV stocks from insect cells. Mol Ther 17 (2009), 1888–1896.
26. 26 Gomori, G, Preparation of Buffers for Use in Enzyme Studies, vol. 1, 1955, Academic Press, New York.
27. 27 Gao, G, Vandenberghe, LH, Alvira, MR, Lu, Y, Calcedo, R, Zhou, X, et al. Clades of Adeno-associated viruses are widely disseminated in human tissues. J Virol 78 (2004), 6381–6388.
28. 28 Aslanidi, G, Lamb, K, Zolotukhin, S, An inducible system for highly efficient production of recombinant adeno-associated virus (rAAV) vectors in insect Sf9 cells. Proc Natl Acad Sci USA 106 (2009), 5059–5064.
29. 29 Zeltner, N, Kohlbrenner, E, Clément, N, Weber, T, Linden, RM, Near-perfect infectivity of wild-type AAV as benchmark for infectivity of recombinant AAV vectors. Gene Ther 17 (2010), 872–879.
30. 30 Clark, KR, Voulgaropoulou, F, Johnson, PR, A stable cell line carrying adenovirus-inducible rep and cap genes allows for infectivity titration of adeno-associated virus vectors. Gene Ther 3 (1996), 1124–1132.